Pfizer Reports Third-Quarter 2009 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3% compared with $12.0 billion in the year-ago quarter. Revenues for third-quarter 2009 compared with the year-ago quarter were unfavorably impacted by approximately $610 million, or 5%, due to foreign exchange and were favorably impacted by $217 million, or 2%, due to a one-time adjustment in the year-ago period for prior years' liabilities for product returns.
Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec®
- Details
- Category: Novartis
- Tasigna produced faster and deeper responses compared to Glivec as first-line treatment in Philadelphia chromosome-positive chronic myeloid leukemia
- First registration study using molecular response as key indicator of patient outcomes; Bcr-Abl biomarker test measures very low levels of residual disease[1],[2]
- First registration study using molecular response as key indicator of patient outcomes; Bcr-Abl biomarker test measures very low levels of residual disease[1],[2]
Abbott Completes Visiogen Acquisition
- Details
- Category: Abbott
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.
FDA approves Cervarix, GlaxoSmithKline's cervical cancer vaccine
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).
FDA approves Micardis® (telmisartan) as the first treatment in its class
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved a new indication for Micardis® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
FDA Approves CRESTOR for Use in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
- Details
- Category: AstraZeneca
AstraZeneca announced the US Food and Drug Administration (FDA) approved CRESTOR (rosuvastatin calcium) for use in children ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.
Pfizer And Wyeth Become One: Working Together For A Healthier Worldâ¢
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.
More Pharma News ...
- Pfizer Completes Acquisition Of Wyeth
- GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
- Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau
- Expert Panel Offers Three-Step Plan to Guide People Toward Recovery of Depression
- Abbott Reports 16.5 Percent Earnings Growth in Third Quarter
- Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM)
- GSK's Avodart® / tamsulosin combination showed benefits for men with prostate enlargement